Personal information

Other IDs

ResearcherID: F-2551-2017

Countries

Canada

Activities

Collapse all

Education and qualifications (3)

Queen's University: Kingston, ON, CA

BSc
Education
Source: Self-asserted source
Melinda Gooderham

Western University: London, ON, CA

1999-05 | MD (Department of Medicine)
Education
Source: Self-asserted source
Melinda Gooderham

University of Guelph: Guelph, ON, CA

1995-05 | MSc (Department of Biochemistry)
Education
Source: Self-asserted source
Melinda Gooderham

Works (50 of 125)

Items per page:
Page 1 of 3

Considerations for defining and diagnosing generalized pustular psoriasis

Journal of the European Academy of Dermatology and Venereology
2025-03 | Journal article
DOI: 10.1111/jdv.20310
Contributors: Vimal H. Prajapati; Charles W. Lynde; Melinda J. Gooderham; H. Chih‐ho Hong; Mark G. Kirchhof; Perla Lansang; Julien Ringuet; Irina Turchin; Ron Vender; Jensen Yeung et al.
Source: check_circle
Crossref

Mission impossible? Caveats in interpreting and comparing long‐term efficacy in biologic studies for moderate‐to‐severe plaque psoriasis

Journal of the European Academy of Dermatology and Venereology
2025-02-22 | Journal article
DOI: 10.1111/jdv.20555
Contributors: Richard G. Langley; Alexander Egeberg; Melinda Gooderham; Robert Bissonnette; Julien Ringuet; Sunil Kalia; Laura Park‐Wyllie; Nastaran Abbarin; Diana Tran; Anthony Zara et al.
Source: check_circle
Crossref

Clinical Characteristics and Treatment Patterns of Pityriasis Rubra Pilaris: A Canadian Retrospective Study

Journal of Cutaneous Medicine and Surgery
2025-01 | Journal article
DOI: 10.1177/12034754241287553
Contributors: Iryna Savinova; Melinda Gooderham; Ashley O’Toole; Ajith Cy; Mohammed Bawazir; Mohannad Abu-Hilal
Source: check_circle
Crossref

Phase II Randomized Trial of BI 730357, an Oral RORγt Inhibitor, for Moderate-to-Severe Plaque Psoriasis

Journal of Investigative Dermatology
2025-01 | Journal article
DOI: 10.1016/j.jid.2024.12.025
Contributors: Melinda J. Gooderham; Ulrich Mrowietz; Werner Kadus; Kristin Drda; Hui Gu; Harald Vangerow; Mary Flack; Julia Korell; Howard Sofen; Kim A. Papp
Source: check_circle
Crossref

Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period

British Journal of Dermatology
2025-01-25 | Journal article
DOI: 10.1093/bjd/ljaf032
Contributors: Richard B Warren; Mark Lebwohl; Diamant Thaçi; Melinda Gooderham; Andreas Pinter; Carle Paul; Paolo Gisondi; Balint Szilagyi; Katy White; Delphine Deherder et al.
Source: check_circle
Crossref

Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials

Dermatology and Therapy
2024-12 | Journal article
DOI: 10.1007/s13555-024-01295-w
Contributors: Joseph F. Merola; Alice B. Gottlieb; Andreas Pinter; Boni Elewski; Melinda Gooderham; Richard B. Warren; Stefano Piaserico; Krista Wixted; Nancy Cross; Nicola Tilt et al.
Source: check_circle
Crossref

Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials

Journal of Dermatological Treatment
2024-12-31 | Journal article
DOI: 10.1080/09546634.2024.2371045
Contributors: Neil J. Korman; Richard B. Warren; Jerry Bagel; April W. Armstrong; Melinda Gooderham; Bruce Strober; Diamant Thaçi; Akimichi Morita; Shinichi Imafuku; Peter Foley et al.
Source: check_circle
Crossref

Combining treat‐to‐target principles and shared decision‐making: International expert consensus‐based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis

Journal of the European Academy of Dermatology and Venereology
2024-11 | Journal article
DOI: 10.1111/jdv.20229
Contributors: Jonathan I. Silverberg; Melinda Gooderham; Norito Katoh; Valeria Aoki; Andrew E. Pink; Yousef Binamer; Marius Rademaker; Daria Fomina; Jan Gutermuth; Jiyoung Ahn et al.
Source: check_circle
Crossref

Dysregulation of epigenetic, biological and mitotic age in the context of biologic drug treatment and phototherapy in plaque psoriasis patients

Journal of the European Academy of Dermatology and Venereology
2024-10 | Journal article
DOI: 10.1111/jdv.19978
Contributors: Richie Jeremian; Yuliya Lytvyn; Rayyan Fotovati; Kaiyang Li; Alexandra Malinowski; Muskaan Sachdeva; Carolyn Jack; Melinda Gooderham; David O. Croitoru; Jensen Yeung et al.
Source: check_circle
Crossref

Practical Recommendations on Laboratory Monitoring in Patients with Atopic Dermatitis on Oral JAK Inhibitors

Dermatology and Therapy
2024-09 | Journal article
DOI: 10.1007/s13555-024-01243-8
Contributors: Mark G. Kirchhof; Vimal H. Prajapati; Melinda Gooderham; Chih-ho Hong; Charles W. Lynde; Catherine Maari; Irina Turchin; Kim A. Papp
Source: check_circle
Crossref

Distinct Signatures of Mitotic Age Acceleration in Cutaneous Melanoma and Acquired Melanocytic Nevi

Journal of Investigative Dermatology
2024-08 | Journal article
DOI: 10.1016/j.jid.2024.01.012
Contributors: Richie Jeremian; Yuliya Lytvyn; Rayyan Fotovati; Jorge R. Georgakopoulos; Melinda Gooderham; Jensen Yeung; Muskaan Sachdeva; Philippe Lefrançois; Ivan V. Litvinov
Source: check_circle
Crossref

Patient-reported burden in adults with atopic dermatitis: an international qualitative study

Archives of Dermatological Research
2024-06-08 | Journal article
DOI: 10.1007/s00403-024-03130-w
Contributors: Andreas Wollenberg; Melinda Gooderham; Norito Katoh; Valeria Aoki; Andrew E. Pink; Yousef Binamer; Jonathan I. Silverberg
Source: check_circle
Crossref

Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)

American Journal of Clinical Dermatology
2024-05 | Journal article
DOI: 10.1007/s40257-024-00853-4
Contributors: Jonathan I. Silverberg; Melinda J. Gooderham; Amy S. Paller; Mette Deleuran; Christopher G. Bunick; Linda F. Stein Gold; DirkJan Hijnen; Brian M. Calimlim; Wan-Ju Lee; Henrique D. Teixeira et al.
Source: check_circle
Crossref

Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial)

Journal of the European Academy of Dermatology and Venereology
2024-05 | Journal article
DOI: 10.1111/jdv.19748
Contributors: Bruce Strober; Hervé Bachelez; Jeffrey Crowley; Boni E. Elewski; Melinda Gooderham; Alan Menter; Robert Strohal; Michael M. Chen; Tianshuang Wu; Tianyu Zhan et al.
Source: check_circle
Crossref

Real-World Experience of Vitiligo Patients: A Retrospective Chart Review

Journal of Cutaneous Medicine and Surgery
2024-03 | Journal article
DOI: 10.1177/12034754231223699
Contributors: Chelsea Obeng-Asumeng; Fabian Rodriguez-Bolanos; Melinda Gooderham
Source: check_circle
Crossref

Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor)

Dermatology and Therapy
2024-02 | Journal article
DOI: 10.1007/s13555-023-01075-y
Contributors: Melinda Gooderham; Ronald Vender; Jeffrey Crowley; H. Chih-Ho Hong; Meghan Feely; Alyssa Garrelts; Kyoungah See; Bruce Konicek; Lawrence Green
Source: check_circle
Crossref

A Practical Guide to Using Biologics in Pediatric Dermatology

Journal of Cutaneous Medicine and Surgery
2024-01 | Journal article
DOI: 10.1177/12034754231222415
Contributors: Annie George; Rafael Paolo Lansang; Perla Lansang; Melinda Gooderham
Source: check_circle
Crossref

Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis and comorbid allergies

Allergy
2024-01 | Journal article
DOI: 10.1111/all.15952
Contributors: Peter Schmid‐Grendelmeier; Melinda J. Gooderham; Karin Hartmann; George N. Konstantinou; Marc Fellmann; Christopher Koulias; Claire Clibborn; Pinaki Biswas; Patrick M. Brunner
Source: check_circle
Crossref

Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2

American Journal of Clinical Dermatology
2024-01 | Journal article
DOI: 10.1007/s40257-023-00810-7
Contributors: Gil Yosipovitch; Melinda J. Gooderham; Sonja Ständer; Luz Fonacier; Jacek C. Szepietowski; Mette Deleuran; Giampiero Girolomoni; John C. Su; Andrew G. Bushmakin; Joseph C. Cappelleri et al.
Source: check_circle
Crossref

Abrocitinib for the Treatment of Atopic Dermatitis

Immunotherapy
2023-11 | Journal article
DOI: 10.2217/imt-2023-0057
Contributors: Ana Maria Lé; Melinda Gooderham; Tiago Torres
Source: check_circle
Crossref

Baseline Characteristics of Canadian Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Journal of Cutaneous Medicine and Surgery
2023-11 | Journal article
DOI: 10.1177/12034754231191509
Contributors: Melinda J. Gooderham; Robert Bissonnette; Sunil Kalia; Kim A. Papp; Lyn C. Guenther; Wayne P. Gulliver; Vincent Ho; Neil H. Shear; Ron Vender; Robert Gniadecki et al.
Source: check_circle
Crossref

Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double‐blind, placebo‐controlled trial

Pediatric Dermatology
2023-11 | Journal article
DOI: 10.1111/pde.15378
Contributors: Maria Hordinsky; Adelaide A. Hebert; Melinda Gooderham; Ohsang Kwon; Nikolay Murashkin; Hong Fang; Kazutoshi Harada; Ernest Law; Dalia Wajsbrot; Liza Takiya et al.
Source: check_circle
Crossref

Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice

Dermatology and Therapy
2023-09 | Journal article
DOI: 10.1007/s13555-023-00948-6
Contributors: Melinda J. Gooderham; Andrew E. Pink; Eric L. Simpson; Jonathan I. Silverberg; Erman Güler; Melissa Watkins
Source: check_circle
Crossref

Real-World Clinical, Psychosocial, and Economic Burden of Atopic Dermatitis: Results From a Multicountry Study.

Journal of the European Academy of Dermatology and Venereology : JEADV
2023-09 | Journal article
DOI: 10.1111/jdv.19500
PMID: 37669868
Contributors: Eyerich K; Gooderham MJ; Silvestre JF; Shumack SP; Mendes-Bastos P; Aoki V; Ortoncelli M; Silverberg JI; Teixeira HD; Chen SH et al.
Source: Self-asserted source
Melinda Gooderham via Europe PubMed Central

The Effectiveness of Risankizumab Following Guselkumab Failure in Moderate-to-Severe Psoriasis Patients: A Retrospective Study

Journal of Cutaneous Medicine and Surgery
2023-09 | Journal article
DOI: 10.1177/12034754231191458
Contributors: Camille Hamm; Nusha Ramsoondar; Michaela McGillis; Miranda Waugh; Melinda Gooderham; Lyne L. Giroux
Source: check_circle
Crossref

Upadacitinib for moderate‐to‐severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics

Journal of the European Academy of Dermatology and Venereology
2023-09 | Journal article
DOI: 10.1111/jdv.19232
Contributors: J. P. Thyssen; D. Thaçi; T. Bieber; M. Gooderham; M. de Bruin‐Weller; W. Soong; K. Kabashima; S. Barbarot; P. C. Luna; J. Xu et al.
Source: check_circle
Crossref

Correction to: Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel

Dermatology and Therapy
2023-08 | Journal article
DOI: 10.1007/s13555-023-00950-y
Contributors: Kim A. Papp; Jennifer Beecker; Curtis Cooper; Mark G. Kirchhof; Anton L. Pozniak; Juergen K. Rockstroh; Jan P. Dutz; Melinda J. Gooderham; Robert Gniadecki; Chih-ho Hong et al.
Source: check_circle
Crossref

Long-Term Multiple Center Experience in Treating Plaque Psoriasis With Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion

Journal of Cutaneous Medicine and Surgery
2023-05 | Journal article
DOI: 10.1177/12034754231163541
Contributors: Abrahim Abduelmula; Melinda J. Gooderham
Source: check_circle
Crossref

Generalized pustular psoriasis: A global Delphi consensus on clinical course, diagnosis, treatment goals and disease management

Journal of the European Academy of Dermatology and Venereology
2023-04 | Journal article
DOI: 10.1111/jdv.18851
Contributors: Lluís Puig; Siew Eng Choon; Alice B. Gottlieb; Slaheddine Marrakchi; Jörg C. Prinz; Ricardo Romiti; Yayoi Tada; Dorothea von Bredow; Melinda Gooderham
Source: check_circle
Crossref

Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry

Dermatology and Therapy
2023-02 | Journal article
DOI: 10.1007/s13555-022-00870-3
Contributors: Melinda Gooderham; Kim A. Papp; Charles Lynde; Isabelle Delorme; Jennifer Beecker; Lorne Albrecht; Ignacio Dei-Cas; Danielle Brassard; Vimal H. Prajapati; Antonio Vieira et al.
Source: check_circle
Crossref

Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials

British Journal of Dermatology
2023-02-22 | Journal article
DOI: 10.1093/bjd/ljac089
Contributors: Georgios Kokolakis; Richard B Warren; Bruce Strober; Andrew Blauvelt; Luis Puig; Akimichi Morita; Melinda Gooderham; Andreas Körber; Veerle Vanvoorden; Maggie Wang et al.
Source: check_circle
Crossref

Reasons for the Termination of Interleukin-17 Inhibitor Medications in the Treatment of Plaque Psoriasis: A Real-World Retrospective Study

Journal of Cutaneous Medicine and Surgery
2023-01 | Journal article
DOI: 10.1177/12034754221143084
Contributors: Athalia Voisin; Aya Al-Ali; Abrahim Abduelmula; Melinda J. Gooderham
Source: check_circle
Crossref

Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program

Dermatology and Therapy
2023-01 | Journal article
DOI: 10.1007/s13555-022-00853-4
Contributors: Wayne Gulliver; Melinda J. Gooderham; Baojin Zhu; Christian Jossart; Sonia Montmayeur; Russel Burge; Catherine Reed
Source: check_circle
Crossref

Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3

Dermatology and Therapy
2022-11 | Journal article
DOI: 10.1007/s13555-022-00805-y
Contributors: Andrew Blauvelt; Melinda Gooderham; Neal Bhatia; Richard G. Langley; Shannon Schneider; John Zoidis; Azra Kurbasic; April Armstrong; Jonathan I. Silverberg
Source: check_circle
Crossref

Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5‐year data from reSURFACE 1 and reSURFACE 2

Journal of the European Academy of Dermatology and Venereology
2022-10 | Journal article
DOI: 10.1111/jdv.18167
Contributors: A.P. Fernandez; E. Dauden; S. Gerdes; M.G. Lebwohl; M.A. Menter; C.L. Leonardi; M. Gooderham; K. Gebauer; Y. Tada; J.P. Lacour et al.
Source: check_circle
Crossref

Achenbach Syndrome (Paroxysmal Finger Hematoma)

Journal of Cutaneous Medicine and Surgery
2022-09 | Journal article
DOI: 10.1177/12034754211073318
Contributors: Claire Chiang; Melinda J. Gooderham
Source: check_circle
Crossref

Practice Patterns Around the Management of Atopic Dermatitis in 2018 and 2020

Journal of Cutaneous Medicine and Surgery
2022-09 | Journal article
DOI: 10.1177/12034754221099669
Contributors: Melinda J. Gooderham; Chih-ho Hong
Source: check_circle
Crossref

High threshold efficacy responses in moderate‐to‐severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents

Journal of the European Academy of Dermatology and Venereology
2022-08 | Journal article
DOI: 10.1111/jdv.18170
Contributors: S. Ständer; N. Bhatia; M. J. Gooderham; J. I. Silverberg; J. P. Thyssen; P. Biswas; M. DiBonaventura; W. Romero; S. A. Farooqui
Source: check_circle
Crossref

Management of Moderate‐to‐Severe Plaque Psoriasis with Biologics: A Treat‐to‐Target Position Paper

Dermatologic Therapy
2022-08-21 | Journal article
DOI: 10.1111/dth.15777
Contributors: Jensen Yeung; Marc Bourcier; Melinda J. Gooderham; Parbeer Grewal; Chih‐Ho Hong; Perla Lansang; Charles Lynde; Catherine Maari; Vimal H. Prajapati; Irina Turchin et al.
Source: check_circle
Crossref

Practice Patterns of Palmoplantar Pustulosis: Patient Demographics and Treatment Options

Journal of Psoriasis and Psoriatic Arthritis
2022-07 | Journal article
DOI: 10.1177/24755303221099292
Contributors: Antoinette Chandler; Hannah Wood; Novin Nezamololama; Melinda J. Gooderham
Source: check_circle
Crossref

Real-World Moderate-to-Severe Hidradenitis Suppurativa: Decrease in Disease Burden With Adalimumab

Journal of Cutaneous Medicine and Surgery
2022-07 | Journal article
DOI: 10.1177/12034754221088584
Contributors: Wayne Gulliver; Afsaneh Alavi; Marni C. Wiseman; Melinda J. Gooderham; Jaggi Rao; Maryam Shayesteh Alam; Kim A. Papp; Olivier Desjardins; Christine Jean
Source: check_circle
Crossref

Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort study

Journal of Dermatological Treatment
2022-07-04 | Journal article
DOI: 10.1080/09546634.2022.2036673
Contributors: Brian D. Rankin; Jorge-Ryan Georgakopoulos; Muskaan Sachdeva; Asfandyar Mufti; Alim R. Devani; Melinda J. Gooderham; Chih-Ho Hong; Vipul Jain; Perla Lansang; Ronald Vender et al.
Source: check_circle
Crossref

Long‐term, durable, absolute Psoriasis Area and Severity Index and health‐related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate‐to‐severe plaque psoriasis

Journal of the European Academy of Dermatology and Venereology
2022-06 | Journal article
DOI: 10.1111/jdv.18010
Contributors: M. Gooderham; A. Pinter; L.K. Ferris; R.B. Warren; T. Zhan; J. Zeng; A.M. Soliman; C. Kaufmann; B. Kaplan; H. Photowala et al.
Source: check_circle
Crossref

Safety of Janus kinase (JAK) inhibitors in the short‐term treatment of atopic dermatitis

International Journal of Dermatology
2022-06 | Journal article
DOI: 10.1111/ijd.15853
Contributors: Hannah Wood; Antoinette Chandler; Novin Nezamololama; Kim Papp; Melinda J. Gooderham
Source: check_circle
Crossref

Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel

Dermatology and Therapy
2022-05 | Journal article
DOI: 10.1007/s13555-022-00722-0
Contributors: Kim A. Papp; Jennifer Beecker; Curtis Cooper; Mark G. Kirchhof; Anton L. Pozniak; Juergen K. Rockstroh; Jan P. Dutz; Melinda J. Gooderham; Robert Gniadecki; Chih-ho Hong et al.
Source: check_circle
Crossref

Clinical, patient and estimated cost benefits of proactive management versus reactive management with calcipotriol/betamethasone dipropionate foam for the treatment of plaque psoriasis in Finland

Journal of Dermatological Treatment
2022-05-19 | Journal article
DOI: 10.1080/09546634.2021.1942419
Contributors: Rauno J. Harvima; Melinda Gooderham; Stephen Tyring; Henrik Thoning; Nanna Nyholm; Linda Stein Gold
Source: check_circle
Crossref

Treatment satisfaction, safety and effectiveness of adding methotrexate to adalimumab in patients with psoriasis responding suboptimally to adalimumab in a real‐world setting

British Journal of Dermatology
2022-04 | Journal article
DOI: 10.1111/bjd.20885
Contributors: K.A. Papp; M.J. Gooderham; L.E. Albrecht; M.‐A. Raymond; C.W. Lynde
Source: check_circle
Crossref

TYK2 inhibition: changing the treatment landscape for psoriasis?

Expert Review of Clinical Immunology
2022-03-04 | Journal article
DOI: 10.1080/1744666X.2022.2008240
Contributors: Abrahim Abduelmula; Melinda J. Gooderham
Source: check_circle
Crossref

The effectiveness of intralesional Candida antigen immunotherapy as a treatment for anogenital warts: a retrospective chart review

Journal of the European Academy of Dermatology and Venereology
2022-02 | Journal article
DOI: 10.1111/jdv.17702
Contributors: M. Logel; R. Pammett; C. Chiang; A. O'Toole; M. Gooderham
Source: check_circle
Crossref

Diagnosis of Generalized Pustular Psoriasis

American Journal of Clinical Dermatology
2022-01 | Journal article
DOI: 10.1007/s40257-021-00652-1
Contributors: Hideki Fujita; Melinda Gooderham; Ricardo Romiti
Source: check_circle
Crossref
Items per page:
Page 1 of 3

Peer review (20 reviews for 5 publications/grants)

Review activity for American journal of clinical dermatology. (11)
Review activity for Clinical drug investigation. (1)
Review activity for Dermatology and therapy. (6)
Review activity for F1000Research. (1)
Review activity for The lancet. (1)
How many people are using ORCID?